Humanized Chemically Defined Medium for Pluripotent Cell Differentiation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for differentiating human embryonic stem cells (hESCs) into progenitor cells of the primary germ layers are limited by their specificity, reliance on undefined components like Foetal Bovine Serum and mouse feeders, and inability to achieve multi-lineage differentiation, which hampers their clinical applications and modeling of early mammalian development.

Innovation Solution

Human pluripotent cells are cultured in a fully humanized chemically defined medium supplemented with specific differentiation factors, allowing controlled differentiation into progenitor cells of the three primary germ layers, including ectoderm, mesoderm, and endoderm, without losing pluripotency, and are purified using techniques like FACS.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If conventional differentiation methods are used, then specific primary germ layer progenitors can be generated, but the methods cannot achieve multi-lineage differentiation and are limited to single lineage

Engineering Contradiction:
Improvemulti-lineage differentiation capabilityVSAvoiddifferentiation efficiency
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The differentiation process is divided into distinct temporal stages: early stage (days 0-3) withActivin A and FGF2 for primitive endoderm formation, middle stage (days 3-7) with BMP4 addition for mesoderm induction, and late stage (days 7-14) with Wnt3A for definitive endoderm specification. This segmented approach enables systematic multi-lineage differentiation while maintaining control over each germ layer's development

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

A single chemically defined medium formulation is designed to support differentiation into all three primary germ layers (ectoderm, mesoderm, endoderm) through sequential addition of differentiation factors. The medium universally supports multi-lineage differentiation without requiring lineage-specific medium changes, thereby achieving both versatility and reliability

Inventive Principle:
Principle #6Universality (Multi-functionality)

2Productivity

If media containing Foetal Bovine Serum and mouse feeders are used, then cell growth is maintained, but clinical applications are limited due to undefined factors and animal-derived components

Engineering Contradiction:
Improvecell growth maintenanceVSAvoidanimal-derived contaminants
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The culture medium composition is fundamentally changed from undefined serum-based formulations to a chemically defined medium with precisely controlled parameters. Specific concentrations of growth factors (Activin A: 10-50 ng/mL, FGF2: 10-50 ng/mL, BMP4: 10-50 ng/mL, Wnt3A: 10-50 ng/mL) are established to maintain cell growth and differentiation capacity without animal-derived components, thereby eliminating contaminants while preserving productivity

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

Recombinant human growth factors and cytokines serve as intermediaries to replace the undefined growth-promoting activities previously provided by Foetal Bovine Serum and mouse feeders. These defined mediators specifically activate signaling pathways (Activin/Nodal, FGF, BMP, Wnt) necessary for differentiation while being free from animal contaminants, thus enabling clinical application

Inventive Principle:
Principle #24Intermediary (Mediator)

3Stability of the object's composition

If undefined cellular matrix and serum are used, then pluripotent cell maintenance is achieved, but the potential for clinical applications and in vitro modeling is limited

Engineering Contradiction:
Improvepluripotent cell maintenanceVSAvoidclinical application potential
Core Design Contradiction:
Stability of the object's compositionVSAdaptability or versatility

Solution Approach 1:

The extracellular matrix composition is changed from undefined animal-derived matrices to defined human-derived alternatives with controlled physical and chemical parameters. Human fibronectin (5-20 μg/cm²) or laminin (5-20 μg/cm²) are used at specific concentrations to maintain cell adhesion and pluripotency while providing a clinically acceptable, contaminant-free substrate that enhances both stability and adaptability

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP2094833B1Differentiation of pluripotent cells into primary germ layer progenitors
Publication Date: 2017.05.17 CAMBRIDGE ENTERPRISE LTD
  • EP2094833B1 patent drawingFigure 1
  • EP2094833B1 patent drawingFigure 2
  • EP2094833B1 patent drawingFigure 3

AI summary

This invention relates to the culture of pluripotent cells in a fully humanised chemically defined medium. Cells may be cultured over a prolonged period of time without losing their pluripotent status or may be controllably induced to differentiate into progenitor cells of the three primary germ layers by the addition of differentiation factors, for example differentiation factors which modulate one or more of the Activin/Nodal, FGF, Wnt or BMP signalling pathways.